KRYSVYJUVEK is still the main character
Krystal Biotech’s first quarter looked a lot like a company that found its golden goose and is happily feeding it. VYJUVEK generated $116.4 million in global revenue in the quarter, bringing cumulative sales since launch to $846.7 million. In biotech land, that’s not just a nice number — it’s the kind of revenue stream that helps turn “promising story” into “actual business.”
The pipeline is trying to join the party
The company also said enrollment is complete in the registrational study for KB803, which is being developed for corneal abrasions in patients with dystrophic epidermolysis bullosa. Translation: one of the next shots on goal is moving forward, and the company expects registrational data in 2026.
Krystal also said it’s on track for 2026 registrational readouts for:
- KB803 in corneal abrasions for DEB patients
- KB801 in NK
That matters because biotech investors don’t just buy current sales — they buy the next act. A strong launch is great, but a pipeline with follow-on catalysts is what keeps the valuation from getting stuck in one-hit-wonder territory.
FDA gave two programs a little badge of honor
The FDA granted platform technology designation to KB407 for cystic fibrosis and KB111 for HHD. That’s not the same as approval, but it is the regulatory version of getting a gold star on your homework. It can help validate the company’s platform and make the development story a little easier to believe.
Cash: the comfort blanket
Krystal ended the quarter with $1.0 billion in cash and investments, which is a pretty cozy cushion for a company pushing multiple programs at once. In biotech, cash is oxygen — and Krystal’s still breathing easy.
Big picture: the quarter says Krystal Biotech is doing the two things investors want most from a biotech: monetizing its lead asset and keeping the pipeline moving. That’s the difference between a one-drug story and a company with some staying power.